Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Leukemia
Sponsor: Hebei Yanda Ludaopei Hospital
This PHASE1 trial investigates Leukemia and is currently ongoing. Hebei Yanda Ludaopei Hospital leads this study, which shows 9 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Dec 2024 — Present [monthly]
Unknown PHASE1
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2022 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
Status: Unknown Status → Not Yet Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Unknown Status PHASE1
Status: Not Yet Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hebei Yanda Ludaopei Hospital
- Kecellitics Biotech Company Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.